SCHEMBL43074

SCHEMBL43074

O=C(Nc1ccccc1F)C1CCCC1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.69
HDAC1 Q13547 1/20 0.69
HDAC2 Q92769 1/20 0.69
KMT2A Q03164 5/20 0.68
MEN1 O00255 4/20 0.68
ALDH1A1 P00352 4/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
GAA P10253 2/20 0.67
POLB P06746 1/20 0.67
CETP P11597 1/20 0.64
SMN1; SMN2 Q16637 3/20 0.63
TSHR P16473 2/20 0.63
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
LMNA P02545 1/20 0.60
HPGD P15428 2/20 0.59
KDM4E B2RXH2 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HSD17B10 Q99714 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13703413 0.98 HDAC3 (0.71) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL4744831 0.93 SMN1; SMN2 (0.67) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL16669873 0.89 ALDH1A1 (0.67) HDAC3HDAC1HDAC2ALDH1A1GAA
SCHEMBL28256535 0.85 CETP (0.77) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL28258088 0.85 CETP (0.77) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL12323604 0.85 CETP (0.77) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL13972908 0.85 SMN1; SMN2 (0.59) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL13588433 0.85 SMN1; SMN2 (0.59) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL2447263 0.84 TNKS (0.58) HDAC3HDAC1HDAC2KMT2AMEN1
SCHEMBL4223097 0.81 HDAC1 (1.00) HDAC3HDAC1HDAC2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3681871-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY Azevan Pharmaceuticals, Inc. (US) 2020-07-22 EP disclosed
WO-2019055913-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2019-03-21 WO disclosed
EP-3122743-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES Azevan Pharmaceuticals, Inc. (US) 2017-02-01 EP disclosed
WO-2015148962-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS, INC. (US) 2015-10-01 WO disclosed
EP-2587919-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER Azevan Pharmaceuticals, Inc. (US) 2013-05-08 EP disclosed
WO-2012003436-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER AZEVAN PHARMACEUTICALS, INC. (US) 2012-01-05 WO disclosed